DATA GRAPHICS | Market Access
Neulasta biosimilars have produced patchy savings for patients
October 9, 2021 1:07 AM UTC
Declining average sales prices for Neulasta and its biosimilars have lowered expenses for Medicare patients, but not necessarily for others
FDA approval of four pegfilgrastim biosimilars has sent the average sales price of the innovator drug, Neulasta, into a tailspin as Amgen has had to offer rebates to payers to maintain market share, but Neulasta’s wholesale acquisition cost has remained high.
The dynamics of Neulasta’s ASP and WAC are playing out differently for different groups of patients. The declining ASP has led to lower out-of-pockets costs for Medicare patients, whose co-insurance is based on ASP, but those with commercial insurance may be making payments based on WAC...